| 
 
 Invited 
            Speaker 
 A Novel Predictive Flip Regression Technique for Qsar of Aromatic 
            Substances: Egfr Inhibitory Activity of Quinazoline Analogues
 Omar Deeb and Brian Clare
 Palestine
  Cancer in the Middle East is an important 
            issue in which approximately 1 in 16,385 or 0.01% are infected annually 
            [1]. Epidermal growth factor receptor (EGFR), identified as a kind 
            of protein tyrosine kinase (PTK), has been demonstrated to be related 
            to many human cancers leading to believe that EGFR is an attractive 
            target for anti-tumor drug discovery.This study has used two relatively new techniques. (1) flip regression 
            [2], for handling the symmetry of the phenylaminoquinazoline system. 
            (2) the use of the orbital nodal angle descriptors [3-6], see Figure 
            1.
 
 
   
 Figure 1. A benzene ring showing the calculated nodal angle 
            (Φ) before 
            and after flipping. X-axis indicates the reference point.
 
 We found excellent regression model between the quinazoline-inhibitory 
            activity of 63 analogues with the selected descriptors [6] in comparison 
            with the results in [7]. It is envisaged that the benzene rings of 
            the quinazolines (Figure 2) are interacting with aromatic systems 
            on the receptor and that alignment occurs between the π-orbital 
            nodes on the pair. The proposed models provide an insight for further 
            designing of new anticancer drugs.
 
 
   Figure 2. Quinazolines skeleton
 References
 
 [1] Freedman LS, Edwards BK, Ries LAG, Young JL (eds). Cancer Incidence 
            in Four Member Countries (Cyprus, Egypt, Israel, and Jordan) of the 
            Middle East Cancer Consortium (MECC) Compared with US SEER. National 
            Cancer Institute. NIH Pub. No. 06-5873. Bethesda, MD.
 
 [2] Clare BW, Supuran CT. Bioorg Med Chem 2005; 13: 2197-2211.
 
 [3] Clare BW. THEOCHEM 2002; 507: 157-164.
 
 [4] Deeb O, Clare BW. J Comput Aided Mol Des 2008; 22: 885-895.
 
 [5] Deeb O, Clare BW. Chem Biol Drug Des 2008; 71(4): 352-362.
 
 [6] Deeb O, Clare BW. J Enzyme Inhib Med Chem 2008; 23(6): 763-775.
 
 [7] Mariano P, Ivanka T, Iliza P. Int J Quant Chem 2006; 106(6):1432.
 
 * This lecture is dedicated to Prof. Brian Clare 
            that Passover in August 2008.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 |